Full Press Release Details
Opus Genetics Announces FDA Clearance of IND Application for Gene Therapy Candidate OPGx-BEST1.
IRD
Opus Genetics Announces FDA Clearance of IND Application for Gene Therapy Candidate OPGx-BEST1
Key Takeaway: Opus Genetics Announces FDA Clearance of IND Application for Gene Therapy Candidate OPGx-BEST1
Price reaction · baseline $1.2 (2025-08-15 close) · clean, no other IRD news in the window
day 0 close · peak
-4.2%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+140%
120-day peak, hindsight
Typical move
6.3%
average across 11 past catalysts
Cash runway
~22 mo
Low dilution risk
Lead asset
APX3330
Phase 2 · Diabetic Retinopathy